Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. reached the public markets through a business combination with Leisure Acquisition Corp. (Nasdaq: LACQ), a blank-check company that completed its IPO in 2018 with an original focus on the leisure and entertainment sector. Ensysce, a clinical-stage pharmaceutical company developing abuse-deterrent opioid therapies and overdose detection technology, was the subject of a 10-K/A amendment filed with the SEC on June 8, 2021, as the de-SPAC transaction moved toward closing. The combined company subsequently listed on Nasdaq under the ticker ENSC, operating in the pharmaceutical and healthcare sector. Sign up for full data on SpacDesk to access complete filing histories, deal timelines, and real-time SPAC analytics.